Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

Endothelial microparticles mediate inflammation‐induced vascular calcification

  • Buendía, Paula
  • Montes de Oca, Addy
  • Madueño, Juan Antonio
  • Merino, Ana
  • Martín Malo, Alejandro
  • Aljama, Pedro
  • Ramírez, Rafael
  • Rodríguez, Mariano
  • Carracedo Añón, Julia María
Stimulation of endothelial cells (ECs) with TNF-α causes an increase in the expression of bone morphogenetic protein-2 (BMP-2) and the production of endothelial microparticles (EMPs). BMP-2 is known to produce osteogenic differentiation of vascular smooth muscle cells (VSMCs). It was found that EMPs from TNF-α-stimulated endothelial cells (HUVECs) contained a significant amount of BMP-2 and were able to enhance VSMC osteogenesis and calcification. Calcium content was greater in VSMCs exposed to EMPs from TNF-α-treated HUVECs than EMPs from nontreated HUVECs (3.56 ± 0.57 vs. 1.48 ± 0.56 μg/mg protein; P < 0.05). The increase in calcification was accompanied by up-regulation of Cbfa1 (osteogenic transcription factor) and down-regulation of SM22α (VSMC lineage marker). Inhibition of BMP-2 by small interfering RNA reduced the VSMC calcification induced by EMPs from TNF-α-treated HUVECs. Similar osteogenic capability was observed in EMPs from both patients with chronic kidney disease and senescent cells, which also presented a high level of BMP-2 expression. Labeling of EMPs with CellTracker shows that EMPs are phagocytized by VSMCs under all conditions (with or without high phosphate, control, and EMPs from TNF-α-treated HUVECs). Our data suggest that EC damage results in the release of EMPs with a high content of calcium and BMP-2 that are able to induce calcification and osteogenic differentiation of VSMCs.
Repisalud
Publication Artículo científico (JournalArticle)

Surgical site infection in hip arthroplasty in a 10-year follow-up prospective study: Risk and factors associated

  • Hijas-Gomez, Ana Isabel
  • Checa-García, Antonio
  • López-Hualda, Álvaro
  • Fahandezh-Saddi, Homid
  • Martínez-Martín, Javier
  • Gil-Conesa, Mario
  • Gil-de-Miguel, Ángel
  • Rodríguez-Villar, Diego
  • Rodríguez-Caravaca, Gil
Background: The increased demand for hip arthroplasty means a growing number of postsurgical complications. This study aims to assess the risk of surgical site infection (SSI) in a teaching hospital; develop regional, national and international external comparisons; and evaluate SSI-related risk factors, particularly according to the timing of surgery (urgent/unplanned or elective). Methods: Prospective cohort study from January 2008 to December 2018. Patients were followed up to 90 days after surgery. Primary endpoint was SSI incidence according to the Centers for Disease Control and Prevention criteria. Multivariate analysis was conducted to find independently associated SSI risk factors. The association between risk factors and SSI incidence was assessed by reference to odds ratio (OR). Analyses were also performed among urgent/unplanned and elective patients to identify whether SSI risk factors differed between groups. Results: The study population (n = 1,808) has an overall SSI rate of 3.0% (95% confidence interval [CI]: 2.4-3.9). Timing of surgery caused an effect modification, so surgery duration> 75th percentile (OR: 3.8; 95% CI: 1.5-9.8) and inadequate preparation (OR: 3.3; 95% CI: 1.1-10.0) were independent risk factors in the urgent/unplanned group; National Healthcare Safety Network risk index≥ 2 (OR: 6.3; 95% CI: 0.1-19.2) and transfusion (OR: 3.6; 95% CI: 1.1-11.9) in the elective group. Conclusions: Hospital infection surveillance systems allow identifying risk factors susceptible to change. Characterization of factors that caused an effect modification is key to identify areas of quality improvement, including reducing operating times, preventing perioperative blood transfusion, or improving patient preparation before surgery.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Circulating Pro-Uroguanylin Levels In Children And Their Relation To Obesity, Sex And Puberty

  • Folgueira Cobos, Cintia
  • Barja Fernández, Silvia
  • González Sáenz, Patricia
  • Castelao, Cecilia
  • Vázquez Cobela, Rocío
  • Pena León, Verónica
  • Ruiz Piñón, Manuel
  • Casanueva Freijo, Felipe
  • Diéguez González, Carlos
  • Leis Trabazo, María Rosaura
  • Nogueiras Pozo, Rubén
  • Seoane, Luisa M.
Uroguanylin is a 16 amino acid peptide that constitutes a key component of the gut- brain axis with special relevance in body weight regulation. In childhood and adolescence, periods of life with notable metabolic changes; limited data exist, with measurements of pro-uroguanylin in adolescence but not in prepubertal children. This study investigates pro-uroguanylin circulating levels in children with obesity and its relationship with obesity, sex and pubertal development. We analyzed circulating prouroguanylin levels in 117 children (62) and adolescents (55), including 73 with obesity and 44 with normal weight. The pro-uroguanylin concentration is higher in lean girls during pre-puberty versus lean boys (1111 vs 635, p < 0.001). During puberty, pro-uroguanylin levels are higher in lean males with respect to lean females (1060 vs 698, p < 0.01). In girls, a negative correlation exists between pro-uroguanylin and age, Tanner stage, weight, height, BMI (body mass index), waist circumference and plasma levels of leptin and testosterone; a positive correlation was found between pro-uroguanylin and free triiodothyronine. In boys, a positive correlation was found between pro-uroguanylin and BMI and waist circumference and a negative correlation was found with high density lipoprotein-cholesterol. We conclude that a sexual dimorphism exists in circulating pro-uroguanylin levels with respect to BMI. Uroguanylin presents also an opposed circulating pattern during puberty in both sexes
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Pharmacological inhibition of cannabinoid receptor 1 stimulates gastric release of nesfatin-1 via the mTOR pathway

  • Folgueira Cobos, Cintia
  • Barja Fernández, Silvia
  • Prado, Laura
  • Al-Massadi, Omar
  • Castelao, Cecilia
  • Pena León, Verónica
  • González Sáenz, Patricia
  • Baltar, Javier
  • Baamonde, Iván
  • Leis Trabazo, María Rosaura
  • Diéguez González, Carlos
  • Pagotto, Uberto
  • Casanueva Freijo, Felipe
  • Tovar Carro, Sulay A.
  • Nogueiras Pozo, Rubén
  • Seoane, Luisa M.
Aim: To determine whether Nucb2/nesfatin1 production is regulated by the cannabinoid system through the intracellular mTOR pathway in the stomach. Methods: Sprague Dawley rats were treated with vehicle, rimonabant, rapamycin or rapamycin+rimonabant. Gastric tissue obtained from the animals was used for biochemical assays: Nucb2 mRNA measurement by real time PCR, gastric Nucb2/nesfatin protein content by western blot, and gastric explants to obtain gastric secretomes. Nucb2/nesfatin levels were measured in gastric secretomes and plasma using enzyme-linked immunosorbent assay. Results: The inhibition of cannabinoid receptor 1 (CB1) by the peripheral injection of an inverse agonist, namely rimonabant, decreases food intake and increases the gastric secretion and circulating levels of Nucb2/nesfatin-1. In addition, rimonabant treatment activates mTOR pathway in the stomach as showed by the increase in pmTOR/mTOR expression in gastric tissue obtained from rimonabant treated animals. These effects were confirmed by the use of a CB1 antagonist, AM281. When the intracellular pathway mTOR/S6k was inactivated by chronic treatment with rapamycin, rimonabant treatment was no longer able to stimulate the gastric secretion of Nucb2/nesfatin-1. Conclusion: The peripheral cannabinoid system regulates food intake through a mechanism that implies gastric production and release of Nucb2/Nesfatin-1, which is mediated by the mTOR/S6k pathway.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

ANGPTL-4 is associated with obesity and lipid profile in children and adolescents

  • Barja-Fernández S.
  • Folgueira C.
  • Castelao C.
  • Pena-León V.
  • González-Saenz P.
  • Vázquez-Cobela R.
  • Aguilera C.M.
  • Gil-Campos M.
  • Bueno G.
  • Gil Á.
  • Moreno L.A.
  • Ruiz-Piñon M.
  • García-Palacios M.
  • Casanueva F.F.
  • Diéguez C.
  • Nogueiras R.
  • Leis R.
  • Seoane L.M.
Angiopoietin-like protein 4 (ANGPTL-4) regulates lipidic metabolism and a_ects energy homeostasis. However, its function in children with obesity remains unknown. We investigated plasma ANGPTL-4 levels in children and its relationship with body mass index (BMI) and di_erent lipidic parameters such as free fatty acids (FFA). Plasma ANGPTL-4 levels were analyzed in two di_erent cohorts. In the first cohort (n = 150, age 3-17 years), which included children with normal weight or obesity, we performed a cross-sectional study. In the second cohort, which included only children with obesity (n = 20, age 5-18 years) followed up for two years after an intervention for weight loss, in which we performed a longitudinal study measuring ANGPTL-4 before and after BMI-loss. In the cross-sectional study, circulating ANGPTL-4 levels were lower in children with obesity than in those with normal weight. Moreover, ANGPTL-4 presented a negative correlation with BMI, waist circumference, weight, insulin, homeostasis model assessment of insulin resistance index (HOMA index), triglycerides, and leptin, and a positive correlation with FFA and vitamin-D. In the longitudinal study, the percent change in plasma ANGPTL-4 was correlated with the percent change in FFA, total-cholesterol and high-density lipoprotein cholesterol. This study reveals a significant association of ANGPTL-4 with pediatric obesity and plasma lipid profile.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Influence of early neurological complications on clinical outcome following lung transplant

  • Gamez Carbonell, Josep
  • Salvadó Figueras, Maria
  • Martínez de la Ossa Vela, Alejandro
  • Deu Martín, María
  • Romero Vielva, Laura Maria
  • Román Broto, Antonio
  • Scanell Lacasa, Judith
  • Laborda Soriano, César
  • Rochera Villach, Ma Isabel
  • Nadal Clanchet, Miriam de
  • Santamarina Pérez, Estevo
  • Raguer Sanz, Nuria
  • Canela Cardona, Mercè
  • Sole Montserrat, Juan
Sistema Nerviós Autònom; Risc de malalties cardiovasculars; Procediments mèdics quirúrgics i invasius, Sistema nervioso autónomo; Riesgo de enfermedad cardiovascular; Procedimientos médicos quirúrgicos e invasivos, Autonomic Nervous System; Cardiovascular disease risk; Surgical and invasive medical procedures, Background Neurological complications after lung transplantation are common. The full spectrum of neurological complications and their impact on clinical outcomes has not been extensively studied. Methods We investigated the neurological incidence of complications, categorized according to whether they affected the central, peripheral or autonomic nervous systems, in a series of 109 patients undergoing lung transplantation at our center between January 1 2013 and December 31 2014. Results Fifty-one patients (46.8%) presented at least one neurological complication. Critical illness polyneuropathy-myopathy (31 cases) and phrenic nerve injury (26 cases) were the two most prevalent complications. These two neuromuscular complications lengthened hospital stays by a median period of 35.5 and 32.5 days respectively. However, neurological complications did not affect patients’ survival. Conclusions The real incidence of neurological complications among lung transplant recipients is probably underestimated. They usually appear in the first two months after surgery. Despite not affecting mortality, they do affect the mean length of hospital stay, and especially the time spent in the Intensive Care Unit. We found no risk factor for neurological complications except for long operating times, ischemic time and need for transfusion. It is necessary to develop programs for the prevention and early recognition of these complications, and the prevention of their precipitant and risk factors., JG is the recipient of a grant from the Spanish Fondo de Investigaciones Sanitarias (FIS PI13-01272-FEDER).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Influence of early neurological complications on clinical outcome following lung transplant

  • Gamez, Josep|||0000-0003-3127-7486
  • Salvado, Maria|||0000-0002-1526-1903
  • Martinez-de La Ossa, Alejandro
  • Deu, Maria
  • Romero, Laura
  • Roman, Antonio
  • Sacanell, Judith
  • Laborda, César
  • Rochera, Isabel
  • Nadal Clanchet, Miriam de|||0000-0002-4559-2463
  • Carmona Jiménez, Francesc|||0000-0001-6474-9860
  • Santamarina Perez, Estevo|||0000-0003-1915-0335
  • Raguer, Nuria|||0000-0002-9471-9096
  • Canela, Mercedes
  • Solé, Joan
Neurological complications after lung transplantation are common. The full spectrum of neurological complications and their impact on clinical outcomes has not been extensively studied. We investigated the neurological incidence of complications, categorized according to whether they affected the central, peripheral or autonomic nervous systems, in a series of 109 patients undergoing lung transplantation at our center between January 1 2013 and December 31 2014. Fifty-one patients (46.8%) presented at least one neurological complication. Critical illness polyneuropathy-myopathy (31 cases) and phrenic nerve injury (26 cases) were the two most prevalent complications. These two neuromuscular complications lengthened hospital stays by a median period of 35.5 and 32.5 days respectively. However, neurological complications did not affect patients' survival. The real incidence of neurological complications among lung transplant recipients is probably underestimated. They usually appear in the first two months after surgery. Despite not affecting mortality, they do affect the mean length of hospital stay, and especially the time spent in the Intensive Care Unit. We found no risk factor for neurological complications except for long operating times, ischemic time and need for transfusion. It is necessary to develop programs for the prevention and early recognition of these complications, and the prevention of their precipitant and risk factors.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CX3CR1 Is a Modifying Gene of Survival and Progression in Amyotrophic Lateral Sclerosis

  • Lopez-Lopez, Alan
  • Gamez, Josep|||0000-0003-3127-7486
  • Syriani, Emilio
  • Morales, Miguel
  • Salvado, Maria|||0000-0002-1526-1903
  • Rodríguez, Manuel J.
  • Mahy, Nicole
  • Vidal-Taboada, Jose M.
The objective of this study was to investigate the association of functional variants of the human CX3CR1 gene (Fractalkine receptor) with the risk of Amyotrophic Lateral Sclerosis (ALS), the survival and the progression rate of the disease symptoms in a Spanish ALS cohort. 187 ALS patients (142 sporadic [sALS] and 45 familial) and 378 controls were recruited. We investigated CX3CR1 V249I (rs3732379) and T280M (rs3732378) genotypes and their haplotypes as predictors of survival, the progression rate of the symptoms (as measured by ALSFRS-R and FVC decline) and the risk of suffering ALS disease. The results indicated that sALS patients with CX3CR1 249 I/I or 249 V/I genotypes presented a shorter survival time (42.27±4.90) than patients with 249 V/V genotype (67.65±7.42; diff -25.49 months 95%CI [-42.79,-8.18]; p = 0.004; adj-p = 0.018). The survival time was shorter in sALS patients with spinal topography and CX3CR1 249 I alleles (diff = -29.78 months; 95%CI [-49.42,-10.14]; p = 0.003). The same effects were also observed in the spinal sALS patients with 249 I -280 M haplotype (diff = -27.02 months; 95%CI [-49.57, -4.48]; p = 0.019). In the sALS group, the CX3CR1 249 I variant was associated with a faster progression of the disease symptoms (OR = 2.58; 95IC% [1.32, 5.07]; p = 0.006; adj-p = 0.027). There was no evidence for association of these two CX3CR1 variants with ALS disease risk. The association evidenced herein is clinically relevant and indicates that CX3CR1 could be a disease-modifying gene in sALS. The progression rate of the disease's symptoms and the survival time is affected in patients with one or two copies of the CX3CR1 249I allele. The CX3CR1 is the most potent ALS survival genetic factor reported to date. These results reinforce the role of the immune system in ALS pathogenesis.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Influence of early neurological complications on clinical outcome following lung transplant

  • Gamez Carbonell, Josep
  • Salvadó Figueras, Maria
  • Martínez de la Ossa Vela, Alejandro
  • Deu Martín, María
  • Romero Vielva, Laura Maria
  • Román Broto, Antonio
  • Scanell Lacasa, Judith
  • Laborda Soriano, César
  • Rochera Villach, Ma Isabel
  • Nadal Clanchet, Miriam de
  • Santamarina Pérez, Estevo
  • Raguer Sanz, Nuria
  • Canela Cardona, Mercè
  • Sole Montserrat, Juan
Sistema Nerviós Autònom; Risc de malalties cardiovasculars; Procediments mèdics quirúrgics i invasius, Sistema nervioso autónomo; Riesgo de enfermedad cardiovascular; Procedimientos médicos quirúrgicos e invasivos, Autonomic Nervous System; Cardiovascular disease risk; Surgical and invasive medical procedures, Background Neurological complications after lung transplantation are common. The full spectrum of neurological complications and their impact on clinical outcomes has not been extensively studied. Methods We investigated the neurological incidence of complications, categorized according to whether they affected the central, peripheral or autonomic nervous systems, in a series of 109 patients undergoing lung transplantation at our center between January 1 2013 and December 31 2014. Results Fifty-one patients (46.8%) presented at least one neurological complication. Critical illness polyneuropathy-myopathy (31 cases) and phrenic nerve injury (26 cases) were the two most prevalent complications. These two neuromuscular complications lengthened hospital stays by a median period of 35.5 and 32.5 days respectively. However, neurological complications did not affect patients’ survival. Conclusions The real incidence of neurological complications among lung transplant recipients is probably underestimated. They usually appear in the first two months after surgery. Despite not affecting mortality, they do affect the mean length of hospital stay, and especially the time spent in the Intensive Care Unit. We found no risk factor for neurological complications except for long operating times, ischemic time and need for transfusion. It is necessary to develop programs for the prevention and early recognition of these complications, and the prevention of their precipitant and risk factors., JG is the recipient of a grant from the Spanish Fondo de Investigaciones Sanitarias (FIS PI13-01272-FEDER).